文献速递消化、代谢与肾脏急症心脑血管急症

替尔泊肽与甘精胰岛素在心血管风险升高的2型糖尿病中的比较(SURPASS-4):一项随机、开放标签、平行组、多中心3期试验

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
PubMed 文献 · Lancet · 2021-10-18

患者随机接受每周一次替尔泊肽5/10/15 mg或甘精胰岛素(滴定至空腹血糖<100 mg/dL)。替尔泊肽低血糖发生率6-9%,低于甘精胰岛素的19%;MACE-4事件未增加。

要点

  • 低血糖(血糖<54 mg/dL或严重)发生率替尔泊肽6-9%低于甘精胰岛素19%;未用磺脲类者替尔泊肽1-3% vs 甘精胰岛素16%。
  • 替尔泊肽恶心12-23%、腹泻13-22%、食欲下降9-11%、呕吐5-9%较甘精胰岛素(2%、4%、<1%、2%)更常见,多为轻中度且见于剂量递增期。

适用人群与场景

  • 研究在14国187个中心开展,为门诊3期试验场景;原文未明确排除标准。

诊断标准与关键阈值

  • 甘精胰岛素(100 U/mL)皮下注射,滴定至空腹血糖<100 mg/dL。
  • 低血糖定义:血糖<54 mg/dL或严重低血糖。
  • MACE-4定义:心血管死亡、心肌梗死、卒中、不稳定心绞痛住院。

处置流程与药物剂量

  • 替尔泊肽5 mg、10 mg或15 mg每周一次皮下注射;甘精胰岛素(100 U/mL)皮下注射并滴定至空腹血糖<100 mg/dL;所有参与者治疗至少52周,最长104周以收集并裁定MACE。
  • 原文未提及替尔泊肽的具体剂量递增方案和疗程细节(除每周一次及至少52周外)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:开放标签、平行组、多中心3期RCT;14国187个中心;筛查3045例,随机2002例,1995例纳入改良意向治疗人群(替尔泊肽5 mg n=329、10 mg n=328、15 mg n=338;甘精胰岛素 n=1000)。
  • 低血糖(血糖<54 mg/dL或严重)发生率:替尔泊肽6-9%,甘精胰岛素19%;未用磺脲类者替尔泊肽1-3% vs 甘精胰岛素16%。
  • 不良事件:恶心12-23%、腹泻13-22%、食欲下降9-11%、呕吐5-9%,均高于甘精胰岛素(2%、4%、<1%、2%),多为轻中度且发生于剂量递增期。

证据类型、等级与局限

  • 证据类型:随机、开放标签、平行组、多中心3期试验(RCT)。
  • 局限:开放标签设计;原文未提及其他局限。

对床旁实践的改变

  • 替尔泊肽胃肠道不良反应(恶心、腹泻、食欲下降、呕吐)较甘精胰岛素常见,多发生于剂量递增期;原文未提供具体处理措施。
  • 原文未提及该研究结果适用于或不应适用于哪些具体人群(除纳入标准外)。

指南或共识出处

  • 原文未提及指南或共识名称;本文为SURPASS-4试验报告(Lancet),注册号NCT03730662,由Eli Lilly and Company资助。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications.

METHODS: This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or older, had type 2 diabetes treated with any combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor, a baseline glycated haemoglobin (HbA1c) of 7·5-10·5% (58-91 mmol/mol), body-mass index of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Participants were randomly assigned (1:1:1:3) via an interactive web-response system to subcutaneous injection of either once-per-week tirzepatide (5 mg, 10 mg, or 15 mg) or glargine (100 U/mL), titrated to reach fasting blood glucose of less than 100 mg/dL. The primary endpoint was non-inferiority (0·3% non-inferiority boundary) of tirzepatide 10 mg or 15 mg, or both, versus glargine in HbA1c change from baseline to 52 weeks. All participants were treated for at least 52 weeks, with treatment continued for a maximum of 104 weeks or until study completion to collect and adjudicate major adverse cardiovascular events (MACE). Safety measures were assessed over the full study period. This study was registered with ClinicalTrials.gov, NCT03730662.

FINDINGS: Patients were recruited between Nov 20, 2018, and Dec 30, 2019. 3045 participants were screened, with 2002 participants randomly assigned to tirzepatide or glargine. 1995 received at least one dose of tirzepatide 5 mg (n=329, 17%), 10 mg (n=328, 16%), or 15 mg (n=338, 17%), or glargine (n=1000, 50%), and were included in the modified intention-to-treat population. At 52 weeks, mean HbA1c changes with tirzepatide were -2·43% (SD 0·05) with 10 mg and -2·58% (0·05) with 15 mg, versus -1·44% (0·03) with glargine. The estimated treatment difference versus glargine was -0·99% (multiplicity adjusted 97·5% CI -1·13 to -0·86) for tirzepatide 10 mg and -1·14% (-1·28 to -1·00) for 15 mg, and the non-inferiority margin of 0·3% was met for both doses. Nausea (12-23%), diarrhoea (13-22%), decreased appetite (9-11%), and vomiting (5-9%) were more frequent with tirzepatide than glargine (nausea 2%, diarrhoea 4%, decreased appetite <1%, and vomiting 2%, respectively); most cases were mild to moderate and occurred during the dose-escalation phase. The percentage of participants with hypoglycaemia (glucose <54 mg/dL or severe) was lower with tirzepatide (6-9%) versus glargine (19%), particularly in participants not on sulfonylureas (tirzepatide 1-3% vs glargine 16%). Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants and were not increased on tirzepatide compared with glargine (hazard ratio 0·74, 95% CI 0·51-1·08). 60 deaths (n=25 [3%] tirzepatide; n=35 [4%] glargine) occurred during the study.

INTERPRETATION: In people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at week 52. Tirzepatide treatment was not associated with excess cardiovascular risk.

FUNDING: Eli Lilly and Company.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021. PMID: 34672967. doi:10.1016/S0140-6736(21)02188-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。